



Felicia Ruffin, PhD, MSN, BSN, BA

Clinical Research Program Leader

Duke University Medical Center

Discovering Disparities in Clinical Characteristics and Outcomes Among Patients Treated in US Hospitals for Carbapenem—Resistant Enterobacterales (Bloodstream) Infections

Felicia Ruffin is a Clinical Research Program Leader at Duke University Medical Center in Durham, North Carolina. For over a decade and a half, she has provided leadership for a large lab focused on translational research designed to understand antimicrobial resistance and the determinants of the outcomes of bacterial infections. Dr. Ruffin's research has defined contemporary microbiology, epidemiology, and outcomes of Gram-positive and Gram-negative bacterial bloodstream infections. Most recently she was awarded an EVERYONE Diversity Seed grant from the Antimicrobial Resistance Leadership Group (ARLG) to evaluate disparities among patients with multidrug resistant (MDR) bacterial infections. Her research interests include the development of interventions that address change at the individual level and social and policy changes that are likely to impact health equity.